5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure.
Wiebke JanssenYves SchymuraTatyana NovoyatlevaBaktybek KojonazarovMario BoehmAstrid WietelmannHimal LuitelKirsten MurmannDamian Richard KrompiecAleksandra TretynSoni Savai PullamsettiNorbert WeissmannWerner SeegerHossein Ardeschir GhofraniRalph Theo SchermulyPublished in: BioMed research international (2015)
5-HT2B receptor antagonists reduce collagen deposition, thereby inhibiting right ventricular fibrosis. Chronic treatment prevented the development and progression of pressure overload-induced RVF in mice. Thus, 5-HT2B receptor antagonists represent a valuable novel therapeutic approach for RVF.